research SALT II: A New Take on the Severity of Alopecia Tool for Determining Percentage Scalp Hair Loss
The updated SALT II tool offers a more precise way to measure scalp hair loss.
Search
for
Sort by
Research
30 / 1000+ results 
research Visualizing Severity Of Alopecia Tool Scores In The Clinical Setting Using Patient Images From A Clinical Trial
The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
research Two-Dimensional Planimetry for Alopecia Areata Severity Evaluation Compared With Severity of Alopecia Tool: A Pilot Study
Measuring bald patch size can help grade hair loss severity, with photograph-based evaluation being more reliable.
research Using Qualitative Methods to Establish the Clinically Meaningful Threshold for Treatment Success for the Severity of Alopecia Tool (SALT) Score
Achieving 80% or more scalp hair regrowth is considered a successful treatment for significant hair loss.
research Efficacy of Baricitinib in Patients With Various Degrees of Alopecia Areata Severity: Results From Brave-AA1 and Brave-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
research Reply to: Serum Vitamin D Level and Disease Severity of Alopecia Areata: A Meta-Regression Analysis
Low vitamin D might be one of several factors involved in the hair loss condition alopecia areata.
research Alopecia Areata: Diagnostic and Therapeutic Recommendations of the Polish Dermatological Society, Part 1: Diagnosis and Severity Assessment
There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.
research Estimation of Claudin 3 in the Serum of Alopecia Areata Patients and Its Association with Disease Severity
Higher Claudin 3 levels in the blood are linked to more severe alopecia areata.
research An Integrated Model of Alopecia Areata Biomarkers Highlights Both Th1/Th2 Upregulation, with Stronger Correlations Between Th2 Activation and Disease Severity
Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.
research Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
research Rethinking The Classification Of Alopecia Areata
The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
research Evaluation of Association of Vitamin D in Alopecia Areata: A Case-Control Study of 100 Patients in a Tertiary Rural Hospital of Southern India
People with alopecia areata often have lower vitamin D levels, which may be linked to the condition's severity.
research Topical Calcipotriol vs Narrowband Ultraviolet B in Treatment of Alopecia Areata: A Randomized-Controlled Trial
Both topical calcipotriol and narrowband UVB improved alopecia, but combining them didn't enhance the effect on hair loss severity, despite higher vitamin D3 levels.
research Clinical Manifestations of Alopecia in Autoimmune Blistering Diseases: A Cross-Sectional Study
Most patients with autoimmune blistering diseases experienced some hair loss, which may be underreported and linked to disease severity.
research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
research Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study
Baricitinib is effective and safe for treating severe alopecia areata.
research Management of Alopecia Areata: Updates and Algorithmic Approach
New treatments for alopecia areata show promise, but no cure exists and responses to treatments vary.
research Cyclosporine for Moderate-to-Severe Alopecia Areata: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety
Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.
research A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research Treatment of Alopecia Areata in Pre-Adolescent Children with Oral Tofacitinib: A Retrospective Study
Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
research Quality of Life in Patients with Alopecia Areata: A Hospital-Based Cross-Sectional Study
Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.
research Efficacy of Postbiotics in a PRP-Like Cosmetic Product for the Treatment of Alopecia Areata: A Randomized Double-Blinded Parallel-Group Study
The PRP-like cosmetic product with postbiotics effectively treats hair loss in Alopecia areata.
research Clinical Experiences on Alopecia Areata Treatment with Tofacitinib: A Study of 63 Patients
Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
research Successful Treatment of Resistant Alopecia Areata with a Phototoxic Dose of Ultraviolet A After Topical 8-Methoxypsoralen Application
This therapy effectively treats resistant alopecia areata with minimal side effects.
research Mild-To-Moderate COVID-19 Is Not Associated With Worsening Of Alopecia Areata: A Retrospective Analysis Of 32 Patients
COVID-19 doesn't make alopecia areata worse.
research Response of Alopecia Areata of the Beard to Oral Tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.